Drug prices receive more scrutiny

Even as pharmaceutical companies develop safer and more effective drugs, the costs of those medications are becoming a concern for healthcare executives, hospitals, payers and patients.

Last July, the U.S. Senate Finance Committee sent a letter to Gilead requesting pricing information for sofosbuvir (Sovaldi), an oral hepatitis C drug that costs $1,000 per pill or $84,000 for a standard 12-week treatment period. The medication was a breakthrough in that it can cure the disease in most patients with few side effects. However, sofosbuvir is becoming a huge budgetary item for Medicare and private payers.

This summer, the FDA approvals of two proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors to lower cholesterol have received national attention because of potential costs concerns. Whereas generic statins can cost less than $50 per year, the wholesale acquisition costs of the PCSK9 inhibitors (alirocumab and evolocumab) are more than $14,000 per year. Payers and patients must now weigh whether the benefits of the new drugs offset the high costs.

Evidence is mounting that the U.S. public is perturbed at the increasing medication costs. On Aug. 20, the Kaiser Family Foundation released a poll that found 72 percent of respondents thought drug prices were unreasonable. In addition, 24 percent said they had trouble paying for their medications.

The poll also revealed that 86 percent of respondents favored requiring companies to release information on how they set their prices. Although drug manufacturers are likely to fight any such law or mandate, the spotlight on rising drug prices is sure to continue. With an added emphasis on value-based healthcare, they will face more pressure to prove that their medications are worth the premium prices and the benefits outweigh the costs.

Tim Casey
Executive Editor - Cardiovascular Business

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup